- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228640
Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3) (NMN)
A Multicentre, Randomized, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN), an Orally Administered Supplementation in Middle Aged and Older Adults.
Study Overview
Detailed Description
Sixty-six healthy male or female middle-aged or older subjects will be assigned in 1:1 ratio to treatment with the test product, NMN or Placebo in this double-blind, randomized, placebo-controlled study. All 66 enrolled subjects will be instructed to take two capsules of either NMN or Placebo once a day after breakfast for 60 days daily. Subjects will be required to use diaries to document the date and time of study treatments including any missed doses and the occurrence of any adverse events.
The duration of each subject's participation in the study will be of 60 days.
Scheduled study visits will include:
- Visit 1 (Screening, Day -4)
- Visit 2 (Baseline/Randomization visit, Day 1)
- Visit 3 (Day 30).
- Visit 4 (End of study, Day 60) A window (± 2 days) will be considered acceptable for each scheduled visit following the baseline visit.
During Visit 1 (Screening), informed consent will be obtained before any study procedures take place. After subject has been consented, medical history will then be documented, including the concomitant medications (if any). Physical examination and ECG will be carried out for all subjects. Subjects' vital signs will be recorded along with pulse pressure (PP).Their laboratory investigations like Hematology, Clinical chemistry and Urinalysis will be done. They shall undergo the screening procedure by inclusion and exclusion criteria. Subject's demography data will be collected. They will be given instructions for the next visit.
At Visit 2 (Day 1, Baseline visit), eligibility confirmation will be done, and each enrolled subject will be randomly assigned in double-blind fashion, in 1:1 ratio to the test product or the Placebo. Blinded investigational product will be dispensed to subjects who meet all the inclusion and none of the exclusion criteria. Subjects will be instructed to take two capsules of the either placebo or NMN once a day with ambient temperature water after breakfast. They shall be recording the dosing details in subject diaries. The first dose of Investigational Product will be taken by the subject at home. Subjects will be evaluated through SF-36 questionnaire for their health. They will be required to answer few questions pertaining to their health. (PI, CRC or site staff will fill SF-36 questionnaire in visit 2, 3 and 4 by asking the subject). All the baseline assessments for efficacy will be performed.
At visit 3 (Day 30) and visit 4 (Day 60), subjects will return to the clinic to review and collect subjects' diaries, safety data, and medication reconciliation. Efficacy and safety assessments will be done at both the visits.
Subjects will be asked to bring their subject diaries and used/unused Investigational Products every time they visit the site. Enough quantity of Investigational Product will be dispensed every visit. Subjects' vital signs will be recorded along with pulse pressure (PP) at all visits. Adverse event assessment and concomitant assessment will be done at each visit along with compliance with drug applications.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Pune, Maharashtra, India, 411019
- Dr Kamalakar Gajarae
-
Pune, Maharashtra, India, 411030
- Swasthiye Clinic and Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male/females of 40 to 65 years of age
- Body Mass Index (BMI) between 18.5 and 35 kg/m2
- Able to provide written Informed Consent
- Able to follow verbal and written study directions
- Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
- Able to maintain consistent diet and lifestyle habits throughout the study
- Male and female subjects must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study
- Willing to consume assigned dietary supplements for 2 months
Exclusion Criteria:
- Participants on current use of prescription or over-the-counter nicotinic acid
- Use of statin drugs
- Having used any tobacco product or used a recreational drug in the past 6 months
- Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator
- Documented presence of atherosclerotic disease and/or cardiopulmonary disease
- History of drug or alcohol abuse
- History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements
- Unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the study start
- Participating in or planning to begin a weight loss diet during the study period
- Chronic use of over-the-counter medication which would interfere with study endpoints
- Lifestyle or schedule incompatible with the study protocol
- Known hypersensitivity to the drug components used during the study
- Women with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding
- Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
- Currently, or within the past 30 days, enrolled in a different clinical investigation
- Inability to provide a venous blood sample
- Unable or unwilling to provide written informed consent for participation in study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational Product
Ingredient: NMN Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
|
Investigational Product
|
Placebo Comparator: Placebo
Ingredient: Starch powder Dosage form: Capsule, 150 mg/capsule Frequency: 2 capsules per day Duration: 60 days
|
Starch Powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood cellular NAD+ concentration in serum
Time Frame: Day 2
|
Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study
|
Day 2
|
Blood cellular NAD+ concentration in serum
Time Frame: Day 30
|
Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study
|
Day 30
|
Blood cellular NAD+ concentration in serum
Time Frame: Day 60
|
Evaluation of Blood cellular NAD+ concentration in serum inter group comparison from baseline to the end of study
|
Day 60
|
Blood cellular NADH concentration in serum
Time Frame: Day 2
|
Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study
|
Day 2
|
Blood cellular NADH concentration in serum
Time Frame: Day 30
|
Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study
|
Day 30
|
Blood cellular NADH concentration in serum
Time Frame: Day 60
|
Evaluation of Blood cellular NADH concentration in serum inter group comparison from baseline to the end of study
|
Day 60
|
Six minutes walking endurance test
Time Frame: Day 2
|
Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study
|
Day 2
|
Six minutes walking endurance test
Time Frame: Day 30
|
Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study
|
Day 30
|
Six minutes walking endurance test
Time Frame: Day 60
|
Evaluation of Six minutes walking endurance test inter group comparison from baseline to the end of study
|
Day 60
|
Systolic
Time Frame: Day 2
|
Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study
|
Day 2
|
Systolic
Time Frame: Day 30
|
Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study
|
Day 30
|
Systolic
Time Frame: Day 60
|
Evaluation of Systolic blood pressure inter group comparison from baseline to the end of study
|
Day 60
|
Diastolic blood pressure
Time Frame: Day 2
|
Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study
|
Day 2
|
Diastolic blood pressure
Time Frame: Day 30
|
Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study
|
Day 30
|
Diastolic blood pressure
Time Frame: Day 60
|
Evaluation of diastolic blood pressure inter group comparison from baseline to the end of study
|
Day 60
|
Pulse pressure
Time Frame: Day 2
|
Evaluation of Pulse Pressure inter group comparison from baseline to the end of study
|
Day 2
|
Pulse pressure
Time Frame: Day 30
|
Evaluation of Pulse Pressure inter group comparison from baseline to the end of study
|
Day 30
|
Pulse pressure
Time Frame: Day 60
|
Evaluation of Pulse Pressure inter group comparison from baseline to the end of study
|
Day 60
|
SF-36 questionnaire
Time Frame: Day 2
|
Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study
|
Day 2
|
SF-36 questionnaire
Time Frame: Day 30
|
Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study
|
Day 30
|
SF-36 questionnaire
Time Frame: Day 60
|
Evaluation of SF-36 questionnaire inter group comparison from baseline to the end of study
|
Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Day 2
|
Evaluation of Adverse events
|
Day 2
|
Adverse events
Time Frame: Day 30
|
Evaluation of Adverse events
|
Day 30
|
Adverse events
Time Frame: Day 60
|
Evaluation of Adverse events
|
Day 60
|
Laboratory parameter (blood chemistry)
Time Frame: Day 1
|
Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study
|
Day 1
|
Laboratory parameter (blood chemistry)
Time Frame: Day 30
|
Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study
|
Day 30
|
Laboratory parameter (blood chemistry)
Time Frame: Day 60
|
Evaluation of Laboratory parameter (blood chemistry) changes from baseline to end of the study
|
Day 60
|
Laboratory parameter (lipid profile)
Time Frame: Day 1
|
Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study
|
Day 1
|
Laboratory parameter (lipid profile)
Time Frame: Day 30
|
Evaluation of Laboratory parameter (blood chemistry, lipid profile, LFT and RFT) changes from baseline to end of the study
|
Day 30
|
Laboratory parameter (lipid profile)
Time Frame: Day 60
|
Evaluation of Laboratory parameter (lipid profile) changes from baseline to end of the study
|
Day 60
|
Laboratory parameter (LFT )
Time Frame: Day 1
|
Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study
|
Day 1
|
Laboratory parameter (LFT)
Time Frame: Day 30
|
Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study
|
Day 30
|
Laboratory parameter (LFT)
Time Frame: Day 60
|
Evaluation of Laboratory parameter (LFT ) changes from baseline to end of the study
|
Day 60
|
Laboratory parameter (RFT)
Time Frame: Day 1
|
Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study
|
Day 1
|
Laboratory parameter (RFT)
Time Frame: Day 30
|
Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study
|
Day 30
|
Laboratory parameter (RFT)
Time Frame: Day 60
|
Evaluation of Laboratory parameter (RFT) changes from baseline to end of the study
|
Day 60
|
Drop out due to adverse events
Time Frame: Day 2
|
Number of participants that dropout due to adverse events including lab values
|
Day 2
|
Drop out due to adverse events
Time Frame: Day 30
|
Number of participants that dropout due to adverse events including lab values
|
Day 30
|
Drop out due to adverse events
Time Frame: Day 60
|
Number of participants that dropout due to adverse events including lab values
|
Day 60
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI
Time Frame: Day 1
|
Monitoring of BMI inter group comparison from baseline to the end of study
|
Day 1
|
BMI
Time Frame: Day 2
|
Monitoring of BMI inter group comparison from baseline to the end of study
|
Day 2
|
BMI
Time Frame: Day 30
|
Monitoring of BMI inter group comparison from baseline to the end of study
|
Day 30
|
BMI
Time Frame: Day 60
|
Monitoring of BMI inter group comparison from baseline to the end of study
|
Day 60
|
HOMA
Time Frame: Day 2
|
Monitoring of HOMA inter group comparison from baseline to the end of study
|
Day 2
|
HOMA
Time Frame: Day 60
|
Monitoring of HOMA inter group comparison from baseline to the end of study
|
Day 60
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ganesh Avhad, Swasthiye Clinic and Research Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EFFE-CT-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Amazentis SAproDERM GmbHCompleted
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
Clinical Trials on NMN
-
Brigham and Women's HospitalBoston Medical CenterRecruitingDiabetic Kidney Disease | Type2diabetesUnited States
-
Peking University Third HospitalRecruitingDiminished Ovarian Reserve | Premature Ovarian InsufficiencyChina
-
Peking University Third HospitalRecruitingPolycystic Ovary SyndromeChina
-
Gilead SciencesCompletedChronic Hepatitis BItaly, United Kingdom, United States, Taiwan, Korea, Republic of, Canada, New Zealand, Hong Kong
-
Shanghai Cell Therapy Group Co.,LtdNot yet recruitingPostoperative Prevention of TumorChina
-
Shanghai Cell Therapy Group Co.,LtdShanghai Mengchao Cancer HospitalNot yet recruiting
-
Washington University School of MedicineCompletedGlucose Metabolism DisordersUnited States
-
Seneque SADicentra Inc.; LGDCompletedHealthy VolunteersCanada
-
Seneque SACEN Biotech; LGDCompletedHealthy VolunteersFrance
-
Société des Produits Nestlé (SPN)Active, not recruiting